Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MANKIND PHARMA Plunges 3%; BSE HEALTHCARE Index Down 0.5%
Mon, 2 Sep 13:58

MANKIND PHARMA Plunges 3%; BSE HEALTHCARE Index Down 0.5%Image source: CreativaImages/www.istockphoto.com

MANKIND PHARMA share price has plunged 3% and is presently trading at Rs 2,409.1.

Meanwhile, the BSE HEALTHCARE index is at 42,972.8 (down 0.5%).

Among the top losers in the BSE HEALTHCARE index today are GRANULES INDIA (down 4.5%) and Dr. Reddys (down 2.7%).

Pfizer (up 4.3%) and MAX HEALTHCARE INSTITUTE (up 1.9%) are among the top gainers today.

Over the last one year, MANKIND PHARMA has moved up from Rs 1,783.0 to Rs 2,409.1, registering a gain of Rs 626.2 (up 35.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,815.8 to 42,972.8, registering a gain of 54.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 127.2%), Glenmark Pharma (up 123.8%) and SUVEN PHARMACEUTICALS (up 115.5%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 82,507.0 (up 0.2%).

The top gainers among the BSE Sensex today are Bajaj Finserv (up 3.5%) and HCl Tech. (up 3.2%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.

In the meantime, NSE Nifty is at 25,258.6 (up 0.1%). Bajaj Finserv and Bajaj Finance are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,075.8 to 82,507.0, registering a gain of 17,431.2 points (up 26.8%).

MANKIND PHARMA Financial Update...

MANKIND PHARMA net profit grew 10.2% YoY to Rs 5,392 million for the quarter ended June 2024, compared to a profit of Rs 4,895 million a year ago. Net sales rose 12.2% to Rs 28,934 million during the period as against Rs 25,786 million in April-June 2023.

For the year ended March 2024, MANKIND PHARMA reported 48.3% increase in net profit to Rs 19,418 million compared to net profit of Rs 13,097 million during FY23. Revenue of the company grew 18.1% to Rs 103,348 million during FY24.

The current Price to earnings ratio of MANKIND PHARMA, based on rolling 12 month earnings, stands at 48.8.


Equitymaster requests your view! Post a comment on "MANKIND PHARMA Plunges 3%; BSE HEALTHCARE Index Down 0.5%". Click here!